Imatinib is also the standard of care, first-line treatment for unresectable or metastatic gastrointestinal stromal tumors [GIST] [50], especially in patients who harbor activating mutations in c-Kit. This evidence concerns the gene KIT and gastrointestinal stromal tumor.